# Clinical trial results:
# A Randomized, Double-Blind, Placebo-controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Pediatric Subjects with Chronic Immune (Idiopathic) Thrombocytopenic Purpura

## Summary

| | |
|---|---|
| EudraCT number | 2007-003569-42 |
| Trial protocol | ES |
| Global end of trial date | 03 March 2009 |

### Results information

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 20 June 2016 |
| First version publication date | 06 August 2015 |

## Trial information

### Trial identification

| | |
|---|---|
| Sponsor protocol code | 20060195 |

### Additional study identifiers

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00515203 |
| WHO universal trial number (UTN) | - |

Notes:

### Sponsors

| | |
|---|---|
| Sponsor organisation name | Amgen, Inc |
| Sponsor organisation address | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320 |
| Public contact | IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com |
| Scientific contact | IHQ Medical Info-Clinical Trials, Amgen (EUROPE) GmbH, MedInfoInternational@amgen.com |

Notes:

### Paediatric regulatory details

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 03 March 2009 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 03 March 2009 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate the safety and tolerability of romiplostim (AMG 531) in the treatment of thrombocytopenia in pediatric subjects with chronic ITP. We will also evaluate the efficacy of romiplostim (AMG 531) and characterize the pharmacokinetics of romiplostim (AMG 531). It is anticipated that romiplostim (AMG 531), when given at an effective dose and schedule, will be well tolerated treatment for thrombocytopenia among pediatric subjects with chronic ITP.

Protection of trial subjects:

This study was conducted in accordance with appropriate country regulations and the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. Essential documents will be retained in accordance with ICH GCP.
Before any subject participated in the study, the investigator was to obtain written informed consent from the subject or legally acceptable representative following adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the study. Informed consent was to be obtained before any protocol-specific screening procedures or administration of investigational product. In addition to written informed consent, the assent of the child from those subjects capable of providing assent must have been obtained if requested by the IRB/IEC.
Copies of the protocol, informed consent form, and other written subject information were submitted to the IEC or IRB for written approval. A copy of the written approval of the protocol and informed consent form was received by Amgen before recruitment of subjects into the study and shipment of investigational product.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 19 July 2007 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Spain: 2 |
| Country: Number of subjects enrolled | United States: 18 |
| Country: Number of subjects enrolled | Australia: 2 |
| Worldwide total number of subjects | 22 |
| EEA total number of subjects | 2 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |

| | |
|---|---|
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 2 |
| Children (2-11 years) | 12 |
| Adolescents (12-17 years) | 8 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled from 19 Jul 2007 through 11 November 2008

### Pre-assignment

Screening details:

Subjects were boys and girls aged 12 months to < 18 years with ITP diagnosed at least 6 months prior to screening and severe thrombocytopenia (mean of 2 screening platelet counts ≤ 30 x 10^9/L with no single count > 35 x 10^9/L). Concurrent corticosteroid therapy was allowed.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Placebo |

Arm description:

Placebo by subcutaneous injection once weekly

| | |
|---|---|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Powder for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Administered by subcutaneous injection

| | |
|---|---|
| **Arm title** | Romiplostim |

Arm description:

Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg.

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Romiplostim |
| Investigational medicinal product code | AMG 531 |
| Other name | Nplate |
| Pharmaceutical forms | Powder for solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Administered by subcutaneous injection

| **Number of subjects in period 1** | Placebo | Romiplostim |
|---|---|---|
| Started | 5 | 17 |
| Completed | 5 | 17 |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Romiplostim |
| Reporting group description: | |
| Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg. | |
| Reporting group title | Placebo |
| Reporting group description: | |
| Placebo by subcutaneous injection once weekly | |

| Reporting group values | Romiplostim | Placebo | Total |
|---|---|---|---|
| Number of subjects | 17 | 5 | 22 |
| Age categorical<br>Units: Subjects | | | |
| 12 months to < 3 years | 3 | 1 | 4 |
| 3 years to < 12 years | 8 | 2 | 10 |
| 12 years to < 18 years | 6 | 2 | 8 |
| Age Continuous<br>Units: Years | | | |
| arithmetic mean | 9.4 | 9.8 | |
| standard deviation | ± 5.4 | ± 4.6 | - |
| Gender, Male/Female<br>Units: Participants | | | |
| Female | 4 | 2 | 6 |
| Male | 13 | 3 | 16 |
| Race, Customized<br>Units: Subjects | | | |
| White or Caucasian | 9 | 4 | 13 |
| Black or African American | 5 | 0 | 5 |
| Hispanic or Latino | 3 | 0 | 3 |
| Other | 0 | 1 | 1 |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Placebo |
| Reporting group description: | |
| Placebo by subcutaneous injection once weekly | |
| Reporting group title | Romiplostim |
| Reporting group description: | |
| Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg. | |

### Primary: Adverse Events

| | |
|---|---|
| End point title | Adverse Events[1] |
| End point description: | |
| Occurrence of one or more adverse events in the participant during the 12-week treatment period. | |
| End point type | Primary |
| End point timeframe: | |
| 12 weeks | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The nature of analyses for this endpoint was descriptive and no formal hypothesis testing was performed.

| End point values | Romiplostim | Placebo | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 17 | 5 | | |
| Units: Participants | | | | |
| number (not applicable) | 16 | 5 | | |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Weeks with Platelet Count ≥ 50 x 10^9/L

| | |
|---|---|
| End point title | Weeks with Platelet Count ≥ 50 x 10^9/L |
| End point description: | |
| The number of weeks with platelet count ≥ 50 x 10^9/L during the 12 week treatment period. | |
| End point type | Secondary |
| End point timeframe: | |
| 12-week treatment period | |

| End point values | Romiplostim | Placebo | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 17 | 5 | | |
| Units: Weeks | | | | |
| arithmetic mean (standard deviation) | 5.65 (± 3) | 0 (± 0) | | |

**Statistical analyses**

| Statistical analysis title | Statistical Analysis |
|---|---|
| Comparison groups | Romiplostim v Placebo |
| Number of subjects included in analysis | 22 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0019 |
| Method | Cochran-Mantel-Haenszel |

**Secondary: Bleeding Events (Grade 2 or higher)**

| End point title | Bleeding Events (Grade 2 or higher) |
|---|---|

End point description:

Total number of bleeding events (Grade 2 or higher, i.e., mild to life-threatening, as defined in the protocol) for each participant during Weeks 2-13 (end-of-study visit for non-responders)

| End point type | Secondary |
|---|---|

End point timeframe:

12-week treatment period (Weeks 2 - 13)

| End point values | Romiplostim | Placebo | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 17 | 5 | | |
| Units: Events per participant | | | | |
| arithmetic mean (standard deviation) | 0.41 (± 1) | 0 (± 0) | | |

**Statistical analyses**

| Statistical analysis title | Statistical Analysis |
|---|---|
| Comparison groups | Romiplostim v Placebo |

| | |
|---|---|
| Number of subjects included in analysis | 22 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.3651 |
| Method | Cochran-Mantel-Haenszel |

## Secondary: Platelet count ≥ 50 x 10^9/L for two consecutive weeks

| | |
|---|---|
| End point title | Platelet count ≥ 50 x 10^9/L for two consecutive weeks |

End point description:

Participant incidence of achieving a platelet count ≥50 x 10^9/L for two consecutive weeks during the 12 week treatment period.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

12-week treatment period

| End point values | Romiplostim | Placebo | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 17 | 5 | | |
| Units: Participants | | | | |
| number (not applicable) | 15 | 0 | | |

### Statistical analyses

| Statistical analysis title | Statistical Analysis |
|---|---|
| Comparison groups | Romiplostim v Placebo |
| Number of subjects included in analysis | 22 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0008 |
| Method | Fisher exact |

## Secondary: Increase in platelet count ≥ 20 x 10^9/L above baseline for two consecutive weeks

| | |
|---|---|
| End point title | Increase in platelet count ≥ 20 x 10^9/L above baseline for two consecutive weeks |

End point description:

Participant incidence of achieving an increase in platelet count ≥20 x 10^9/L above baseline for two consecutive weeks during the 12 week treatment period.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

12-week treatment period

| End point values | Romiplostim | Placebo | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 17 | 5 | | |
| Units: Participants | | | | |
| number (not applicable) | 15 | 0 | | |

**Statistical analyses**

| Statistical analysis title | Statisticla Analysis |
|---|---|
| Comparison groups | Romiplostim v Placebo |
| Number of subjects included in analysis | 22 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0008 |
| Method | Fisher exact |

| Secondary: Requirement for Rescue Therapy (as defined per protocol) | |
|---|---|
| End point title | Requirement for Rescue Therapy (as defined per protocol) |
| End point description:<br>Participant required rescue therapy (as defined per protocol) during the 12 week treatment period. | |
| End point type | Secondary |
| End point timeframe:<br>12-week treatment period | |

| End point values | Romiplostim | Placebo | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 17 | 5 | | |
| Units: Participants | | | | |
| number (not applicable) | 2 | 2 | | |

**Statistical analyses**

| Statistical analysis title | Statistical Analysis |
|---|---|
| Comparison groups | Romiplostim v Placebo |

| | |
|---|---|
| Number of subjects included in analysis | 22 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.2098 |
| Method | Fisher exact |

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

16 weeks

| | |
|---|---|
| Assessment type | Systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 16.1 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Placebo |

Reporting group description:

Placebo by subcutaneous injection once weekly

| | |
|---|---|
| Reporting group title | Romiplostim |

Reporting group description:

Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg

| Serious adverse events | Placebo | Romiplostim | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 17 (11.76%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | | | |
| Blood and lymphatic system disorders | | | |
| Lymphadenitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Influenza | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Placebo | Romiplostim | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 5 / 5 (100.00%) | 16 / 17 (94.12%) | |
| Vascular disorders | | | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Haemorrhage | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 17 (11.76%) | |
| occurrences (all) | 0 | 2 | |
| General disorders and administration site conditions | | | |
| Chest discomfort | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Injection site haematoma | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Injection site haemorrhage | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Malaise | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 5 / 17 (29.41%) | |
| occurrences (all) | 0 | 6 | |
| Immune system disorders | | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Reproductive system and breast disorders | | | |

| | | | |
|---|---|---|---|
| Genital haemorrhage | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Menorrhagia | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Vaginal discharge | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Cough | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 2 / 17 (11.76%) | |
| occurrences (all) | 3 | 2 | |
| Dyspnoea exertional | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Epistaxis | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 6 / 17 (35.29%) | |
| occurrences (all) | 1 | 8 | |
| Nasal congestion | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 4 / 17 (23.53%) | |
| occurrences (all) | 0 | 4 | |
| Pharyngeal erythema | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Respiratory tract congestion | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Rhinorrhoea | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Wheezing | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Psychiatric disorders | | | |
| Emotional disorder | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Investigations | | | |
| Spleen palpable | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Injury, poisoning and procedural complications | | | |
| Contusion | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 3 / 17 (17.65%) | |
| occurrences (all) | 3 | 4 | |
| Fall | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Scratch | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Skin laceration | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 1 | 1 | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Headache | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 6 / 17 (35.29%) | |
| occurrences (all) | 2 | 11 | |
| Blood and lymphatic system disorders | | | |
| Thrombocytopenia | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 2 | 1 | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 3 / 17 (17.65%) | |
| occurrences (all) | 0 | 4 | |
| Chapped lips | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Diarrhoea | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 17 (11.76%) | |
| occurrences (all) | 0 | 2 | |
| Mouth haemorrhage | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Toothache | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Vomiting | | | |
| subjects affected / exposed | 2 / 5 (40.00%) | 2 / 17 (11.76%) | |
| occurrences (all) | 2 | 2 | |
| Skin and subcutaneous tissue disorders | | | |
| Erythema | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Hyperhidrosis | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Petechiae | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 2 / 17 (11.76%) | |
| occurrences (all) | 2 | 3 | |
| Pruritus | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 4 | |
| Rash | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 3 / 17 (17.65%) | |
| occurrences (all) | 0 | 5 | |
| Rash macular | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 3 | |
| Skin nodule | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Renal and urinary disorders | | | |
| Dysuria | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Urethral disorder | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Back pain | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 1 | 1 | |
| Inguinal mass | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 1 | 1 | |
| Infections and infestations | | | |
| Ear infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Herpes simplex | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 5 (20.00%) | 0 / 17 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 2 / 17 (11.76%) | |
| occurrences (all) | 0 | 2 | |
| Otitis media | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Otitis media acute | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 1 / 5 (20.00%) | 2 / 17 (11.76%) | |
| occurrences (all) | 2 | 3 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 5 (0.00%) | 1 / 17 (5.88%) | |
| occurrences (all) | 0 | 1 | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 01 August 2007 | Major Changes:<br>• Replaced the use of the romiplostim diluent with a commercially available diluent. |
| 04 September 2008 | Major Changes:<br>• Updated consent form to provide updated patient exposure numbers and percentage of subjects who have reported adverse events. |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported